Valsartan Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism: A randomized controlled trial

OBJECTIVE: Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB) valsartan for 5 years resulted in a relative reduction of 14% in the incidence of type 2 diabetes in subjects with impaired...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Zijl, Nynke J., Moors, Chantalle C.M., Goossens, Gijs H., Hermans, Marc M.H., Blaak, Ellen E., Diamant, Michaela
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064038/
https://www.ncbi.nlm.nih.gov/pubmed/21330640
http://dx.doi.org/10.2337/dc10-2224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064038/
https://www.ncbi.nlm.nih.gov/pubmed/21330640
http://dx.doi.org/10.2337/dc10-2224

Ejemplares similares